C4 Therapeutics, Inc Share Price Today: Live Updates & Key Insights
C4 Therapeutics, Inc share price today is $3.435, up -6.85%. The stock opened at $3.66 against the previous close of $3.65, with an intraday high of $3.66 and low of $3.39.
C4 Therapeutics, Inc Share Price Chart
C4 Therapeutics, Inc
C4 Therapeutics, Inc Share Price Performance
C4 Therapeutics, Inc Institutional Holdings
C4 Therapeutics, Inc Market Status
C4 Therapeutics, Inc Fundamentals
Market Cap 403.57 M
PB Ratio 1.7653
PE Ratio 0.0
Enterprise Value 227.45 M
Total Assets 359.08 M
Volume 2584074
C4 Therapeutics, Inc Company Financials
About C4 Therapeutics, Inc & investment objective
Company Information C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Organisation Biotechnology
Employees 104
Industry Biotechnology
CEO Mr. Andrew J. Hirsch M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
C4 Therapeutics, Inc FAQs
What is the share price of C4 Therapeutics, Inc today?
The current share price of C4 Therapeutics, Inc is $3.435.
Can I buy C4 Therapeutics, Inc shares in India?
Yes, Indian investors can buy C4 Therapeutics, Inc shares by opening an international trading and demat account with Motilal Oswal.
How to buy C4 Therapeutics, Inc shares in India?
You can easily invest in C4 Therapeutics, Inc shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy C4 Therapeutics, Inc shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of C4 Therapeutics, Inc.
Can I buy fractional shares of C4 Therapeutics, Inc?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of C4 Therapeutics, Inc?
C4 Therapeutics, Inc has a market cap of $403.57 M.
In which sector does C4 Therapeutics, Inc belong?
C4 Therapeutics, Inc operates in the Biotechnology sector.
What documents are required to invest in C4 Therapeutics, Inc stocks?
To invest, you typically need:
What is the PE and PB ratio of C4 Therapeutics, Inc?
The PE ratio of C4 Therapeutics, Inc is N/A and the PB ratio is 1.77.